

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	1/15/04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Mills, T. M. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-267875

Express Mail Certificate EV 032 197 074 US

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
JUN 27 2002
MAIL CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SAC	1	4,127,118		Latorre, Alvaro	11-28-78	
	2	4,801,587		Voss, Gene et al.	01-31-89	
	3	4,968,679		Bodo Junge, Wuppertal et al.	11-06-90	
	4	5,059,603		Rubin, David	10-22-91	
	5	5,242,391		Place, V. A. et al.	09-07-93	
	6	5,256,652		El-Rashidy, Ragab	10-26-93	
	7	5,888,534		El-Rashidy, Ragab et al.	03-30-99	
	8	5,945,117		El-Rashidy, Ragab et al.	08-31-99	
	9	5,981,563		Lowrey, Fred	11-09-99	
	10	6,007,824		Duckett, M. J. et al.	12-28-99	
	11	6,051,594		Lowrey, Fred	04-18-00	
	12	6,087,362		El-Rashidy, Ragab	07-11-00	
	13	6,093,181		Place, V. A. et al.	07-25-00	
	14	6,100,270		Campbell, S. F.	08-08-00	
	15	6,100,286		Lowrey, Fred	08-08-00	
	16	6,124,337		Lowrey, Fred	09-26-00	
	17	6,166,061		Lowrey, Fred	12-26-00	
SAC	18	6,239,117 B1		Christ, G. J. et al.	05-29-01	
	19	6,266,560 B1		Zhang, L. et al.	07-24-01	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ³
		Office ³	Number ⁴	Kind Code ² (if known)				
SAC	20	BG	103246A (abstract translation)		Yoshitomi Pharmaceutical Industries Ltd.	05-31-00		✓
	21	EP	0633023A1		Eli Lilly & Co.	01-11-95		✓
	22	JP	7048254 (abstract translation)		Eli Lilly & Co.	02-21-95		✓
	23	WO	98/06433 (abstract translation)		Yoshitomi Pharmaceutical Industries Ltd.	02-19-98		✓
SAC	24	WO	00/33845 (abstract translation)		Yoshitomi Pharmaceutical Industries Ltd.	06-15-00		✓

Examiner Signature

Date Considered

4/15/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTD/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0337

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUN 27 2002

RECEIVED
TELEFAX CENTER
JUN 27 2002
1600 P 2000

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Mills, T. M. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-267875

Sheet 2 of 4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SAC	25	AMANO, M., et al., Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase), <i>J. Biol. Chem.</i> , 271 , 20246-20249, 1996	✓
	26	ANDERSSON, K.E., Pharmacology of Penile Erection, <i>Pharmacol. Rev.</i> , 53 , 417-450, September 2001	✓
	27	APENSTROM, P., Effectors for the RHO GTPases, <i>Curr. Opin. Cell. Biol.</i> , 11 , 95-102, 1999	✓
	28	BERMAN, J.R., et al., Anatomy and Physiology of Female Sexual Function and Dysfunction, <i>Eur. Urology</i> 38 , 20-29, 2000	✓
	29	BIVALACQUA, T.J., et al., Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat, <i>Int. J. Impotence Res.</i> , 12 , S8-S17, September 2000	✓
	30	BURNETT, A.L., Role of Nitric Oxide in the Physiology of Erection, <i>Biol. Reprod.</i> , 52 , 485-489, 1995	✓
	31	CHAMPION, H.C., et al., Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat, <i>Proc. Natl. Acad. Sci., USA</i> , 96 , 11648-11652, 1999	✓
	32	CHITALEY, K., et al., Antagonism of Rho-kinase stimulates rate penile erection via nitric oxide-independent pathway, <i>Nature Med.</i> , 7 , 119-122, January 2001	✓
	33	CHITALEY, K., et al., RhoA/Rho-kinase: a novel player in the regulation of penile erection, <i>Int'l J. of Impotence Research</i> , 13 , 67-72, April 2001	✓
	34	CHITALEY, K., et al., Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats, <i>Int'l J. of Impotence Research</i> , 13 , Suppl 5, S16-S20, December 2001	✓
	35	CHRIST, G.J., et al., The application of gene therapy to the treatment of erectile dysfunction, <i>Int. J. Impotence Res.</i> , 10 , 111-112, 1998	✓
	36	CHRIST, G. J., et al., Intracorporal injection of <i>hSlc</i> cDNA in rats produces physiologically relevant alterations in penile function, <i>Am. J. Physiol.</i> , 275 , H600-608, 1998	✓
	37	DAI, Y., et al., Receptor-specific influence of endothelin-1 in the erectile response of the rat, <i>Am. J. Physiol. Regulatory Integrative Compl. Physiol.</i> , 279 , R25-R30, July 2000	✓
	38	DiSALVO, J., et al., Vanadate-Induced Contraction of Smooth Muscle and Enhanced Protein Tyrosine Phosphorylation, <i>Arch. Biochem. Biophys.</i> , 304 , 386-391, 1993	✓
	39	DUCKERS, H.J., et al., Heme oxygenase-1 protects against vascular constriction and proliferation, <i>Nature Med.</i> , 7 , 693-698, June 2001	✓
	40	FENG, et al., Rho-associated Kinase of Chicken Gizzard Smooth Muscle, <i>J. Biol Chem.</i> , 274 , 3744-3752, 1999	✓
	41	GARBAN, H., et al., Cloning of Rat and Human Inducible Penile Nitric Oxide Synthase. Application for Gene Therapy of Erectile Dysfunction, <i>Biol. Reprod.</i> , 56 , 954-963, 1997	✓
	42	ISHIZAKI, T., et al., Pharmacological Properties of Y-27632, a Specific	✓

SAC 1/15/04

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

JUN 27 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Mills, T. M. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-267875

TECH CENTER 1800 P 900
JUL 8 2002

390		Inhibitor of Rho-associated Kinases, <i>Mol. Pharmacol.</i> , 57 , 976-983, May 2000	
	43	JAROW, I.P., et al., Clinical Efficacy of Sildenafil Citrate Based on Etiology and Response to Prior Treatment <i>J. Urology</i> 162 , 722-725, 1999	✓
	44	KIMURA, K., et al., Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase), <i>Science</i> , 273 , 245-248, 1997	✓
	45	KUREISHI, Y., et al., Rho-associated Kinase Directly Induces Smooth Muscle Contraction through Myosin Light Chain Phosphorylation, <i>J. Biol. Chem.</i> , 272 , 12257-12260, 1997	✓
	46	LOWRY, O.H., et al., Protein Measurement with the Folin Phenol Reagent, <i>J. Biol. Chem.</i> , 193 , 265-275, 1951	✓
	47	MILLS, T., et al., Androgen Maintenance of Erectile Function in the Rat Penis, <i>Biol. Reprod.</i> , 46 , 342-348, 1992	✓
	48	MILLS, T., et al., Effects of Castration and Androgen Replacement on the Hemodynamics of Penile Erection in the Rat, <i>Biol. Reprod.</i> , 51 , 234-238, 1994	✓
	49	MILLS, T., et al., Androgenic Maintenance of the Erectile Response in the Rat, <i>Steroids</i> , 64 , 605-609, 1999	✓
	50	MILLS, T., et al., Androgenic Maintenance of Inflow and Veno-Occlusion during Erection in the Rat, <i>Biol. Reprod.</i> , 59 , 1413-1418, 1998	✓
	51	MILLS, T., et al., The Effect of an Inhibitor of Rho Kinase on the Erectile Response, <i>Int'l J. of Impotence Research</i> , Suppl 3, Abstract A1, September 2000	✓
	52	MILLS, T., et al., Inhibition of the Rho Kinase Pathway Leads to Penile Erection, <i>9th World Meeting on Impotence Research</i> , Perth Australia, Abstract P6, Nov. 26-30, 2000	✓
	53	MILLS, T., et al., Vasoconstrictors in erectile physiology, <i>Int'l J. of Impotence Research</i> , 13 , Suppl 5, S29-S34, December 2001	✓
	54	MILLS, T., et al., Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation, <i>J. Appl. Physiol.</i> , 91 , 1269-1273, September 2001	✓
	55	MILLS, T., New Biochemical Pathway May Control Erection, <i>TheScientificWorld</i> , 1 , 184-185, May 2001	✓
	56	MOODY, J.A., et al., Effects of Long-Term Oral Administration of L-Arginine on the Rat Erectile Response, <i>J. Urology</i> , 158 , 942-947, 1997	✓
	57	OKAMURA, T., et al., Monkey corpus cavernosum relaxation mediated by NO and other relaxing factor derived from nerves, <i>Am J. Physiol.</i> , 274 , H1075-H1081, 1998	✓
	58	PFITZER, G., et al., Involvement of small GTPases in the regulation of smooth muscle contraction, <i>Acta Physiol. Scand.</i> , 164 , 449-456, 1998	✓
	59	REES, R. W., et al., Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contraction in the rabbit and human penile corpus cavernosum, <i>British J. of Pharmacology</i> , 133 , 455, June 2001	✓
	60	REES, R. W., et al., Human and rabbit cavernosal smooth muscle cells express Rho-kinase, <i>Int'l J. of Impotence Research</i> , 14 , 1-7, February 2002	✓
390	61	REILLY, C.M., et al., Androgens Modulate the α-Adrenergic Responsiveness of Vascular Smooth Muscle in the Corpus Cavernosum, <i>J.</i>	✓

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO

JUN 27 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Mills, T. M. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-267875

<i>SAC</i>	<i>SAC</i>	of Andrology, 1, 26-31, 1997	
	62	REILLY, C.M., et al., Androgenic Regulation of NO Availability in Rat Penile Erection, <i>J. Andrology</i> , 18 , 110-115, 1997	✓
	63	REILLY, C.M., et al., Androgenic Maintenance of the Rat Erectile Response Via a Non-Nitric-Oxide-Dependent Pathway, <i>J. Andrology</i> , 18 , 588-594, 1997	✓
	64	RIDLEY, A., RHO: theme and variations, <i>Curr. Biol.</i> , 6 , 1256-1264, 1996	✓
	65	SAHAI, E., et al., RhoA effector mutants reveal distinct effector pathways for cytoskeletal reorganization, SRF activation and transformation, <i>EMBO J.</i> , 17 , 1350-1361, 1998	✓
	66	SAUZEAU, V., et al., Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca ²⁺ Sensitization of Contraction in Vascular Smooth Muscle, <i>J. Biol. Chem.</i> , 275 , 21722-21729, July 2000	✓
	67	SAWADA, N., et al., cGMP-Dependent Protein Kinase Phosphorylates and Inactivates RhoA, <i>Biochem. Biophys. Res. Comm.</i> , 280 , 798-805, January 26, 2001	✓
	68	SCHOTT, E., et al., Expression of a recombinant preproendothelin-1 gene in arteries stimulates vascular contractility, <i>Am. J. Physiol.</i> , 272 , H2385-H2393, 1997	✓
	69	SOMLYO, A.P., et al., From pharmacomechanical coupling to G-proteins and myosin phosphatase, <i>Acta Physiol. Scand.</i> , 164 , 437-448, 1998	✓
	70	SOMLYO, et al., Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II, <i>J. Physiol.</i> , 522 , 177-185, January 2000	✓
	71	TRAISH, A., et al., Role of alpha adrenergic receptors in erectile function, <i>Int. J. Impot. Res.</i> , 12 , Suppl. 1, S48-63, March 2000	✓
	72	UEHATA, M., et al., Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension, <i>Nature</i> , 389 , 990-994, 1997	✓
	73	VIRAG R., Indications and Early Results of Sildenafil (VIAGRA) in Erectile Dysfunction, <i>Urology</i> 54 , 1073-77, 1999	✓
	74	WEBER, et al., Enhanced Relaxation to the Rho-Kinase Inhibitor Y-27632 in Mesenteric Arteries from Mineralocorticoid Hypertensive Rats, <i>Pharmacology</i> , 63 , 129-133, October 2001	✓
	75	WINGARD, C. J., et al., Recovery of Penile Erection by Inhibition of Rho-Kinase in a Castrate Rat Model of Erectile Dysfunction, <i>Int'l J. of Impotence Research</i> , 13 , Suppl 5, Abstract 1, December 2001	✓
<i>SAC</i>	76	WINGARD, C. J., et al., Erection and NO override the vasoconstrictive effect of α-adrenergic stimulation in the rat penile vasculature, <i>Int'l J. of Impotence Research</i> , 13 , 212-220, August 2001	✓
Examiner Signature	<i>SAC</i>	Date Considered	1/15/04


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

M0351-267875 WINLIB01:932491.1



OCT 06 2003

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. GMD 003-1-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449APTO
**3rd SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<i>Complete if Known</i>	
Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Thomas M. Mills
Group Art Unit	1617
Examiner Name	Bahar, Mojdeh
Attorney Docket Number	M0351-267875 (011-00)

Sheet 1 of

Express Mail Certificate EV 315 188 141 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner
Signature

Date Considerations

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: A-11-12-A-1-A-1-B-1-W-11-10-1000

M0351-267875
WINLIB01: 1033460.1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 1992-06-30. GPO 1991 0307

Substitute for Form 1449APTO
**2nd SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Street 2 of 2

Complete if Known

Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Thomas M. Mills
Group Art Unit	1617
Examiner Name	Hui, San Ming R.
Attorney Docket Number	M0351-267875 (011-00)
Express Mail Certificate	EV 127 539 264 US

APR 21 2003

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

M0351-267875
WINLIB01:1002297.1


Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449APTO

**2nd SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

<i>Complete if Known</i>	
Application Number	10/040,010
Filing Date	January 4, 2002
First Named Inventor	Thomas M. Mills
Group Art Unit	1617
Examiner Name	Hui, San Ming R.
Attorney Docket Number	M0351-267875 (011-00)
Express Mail Certificate	EV 127 539 264 US

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

SECRET

Date Considered

1/15/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and do not consider. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.